抗肥満薬の市場規模、シェア、動向、予測：薬剤クラス別、薬剤タイプ別、流通チャネル別、地域別、2025年～2033年

抗肥満薬の世界市場規模は2024年に25億米ドルとなりました。今後、IMARC Groupは、同市場が2033年までに59億米ドルに達し、2025年から2033年にかけて9.89％のCAGRを示すと予測しています。現在、北米が市場を独占しており、2024年の市場シェアは36.7％を超えます。抗肥満薬の市場シェアは、肥満率の上昇、健康意識、体重管理ソリューションの需要、医薬品開発の進展、政府の取り組み、研究開発投資、併用療法、処方薬や市販薬の入手可能性などにより増加しています。

抗肥満薬は、体重の減少やコントロールを目的とし、一般的には病的な肥満の場合にのみ医学的に処方されます。これらの薬は、特に甘いものや脂肪分、塩分、高カロリーの食品に対する欲求を抑え、強迫的な摂食をコントロールするのに役立ちます。また、血圧、有害脂質レベル、ウエスト周囲径、糖度、非アルコール性脂肪性肝疾患（NAFLD）をコントロールし、主要な心血管疾患（CVD）のリスクや糖尿病性腎臓病の進行を最小限に抑えるなど、独立した健康上の利益をもたらすことができます。

抗肥満薬の市場動向：

最近の抗肥満薬の進歩により、臨床的に大幅な体重減少を達成できる可能性が出てきました。このことは、座りがちなライフスタイルのために肥満が広く蔓延していることと相まって、市場に明るい展望をもたらす重要な要因の一つとなっています。加えて、肥満は2型糖尿病（T2D）、心血管疾患（CVD）、食道、結腸・直腸、肝臓、胆嚢、膵臓、腎臓のがんの発症リスクを高める。また、多くの精神疾患、神経疾患、肺疾患、胃腸疾患、腎疾患、筋骨格系疾患、内分泌疾患を引き起こす可能性があります。これに加えて、睡眠不足、概日リズムの狂い、慢性的なストレス、抗てんかん薬や向精神薬の使用増加などが、体重増加をさらに誘発する可能性があります。このことは、食欲や食への欲求を調整する抗肥満薬（AOMs）の承認件数の増加と相まって、市場の成長に拍車をかけています。これとは別に、減量は個人の生活の質、運動能力、日常生活機能、心理的幸福の向上に役立ちます。これに加えて、健康志向の高まり、製薬業界の繁栄、過剰体重と密接に関連する疾患の管理への注目の高まりが、市場の成長を刺激すると予想されます。

本レポートで扱う主な質問

• 抗肥満薬の市場の規模は？
• 抗肥満薬の市場の将来展望は？
• 抗肥満薬の市場を牽引する主要因は何か？
• 抗肥満薬の市場で最大のシェアを占める地域は？
• 世界の抗肥満薬の市場における主要企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界の抗肥満薬市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：薬剤クラス別

• 末梢作用薬
• 中枢作用薬

第7章 市場内訳：薬剤クラス別

• 処方薬
• 市販薬

第8章 市場内訳：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場内訳：国別

第10章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第13章 価格分析

第14章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals LLC
  • Gelesis
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Norgine B.V.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Rhythm Pharmaceuticals Inc.
  • SHIONOGI & Co. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vivus LLC

List of Figures

• Figure 1: Global: Anti-Obesity Drugs Market: Major Drivers and Challenges
• Figure 2: Global: Anti-Obesity Drugs Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Anti-Obesity Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 4: Global: Anti-Obesity Drugs Market: Breakup by Drug Class (in %), 2024
• Figure 5: Global: Anti-Obesity Drugs Market: Breakup by Drug Type (in %), 2024
• Figure 6: Global: Anti-Obesity Drugs Market: Breakup by Distribution Channel (in %), 2024
• Figure 7: Global: Anti-Obesity Drugs Market: Breakup by Region (in %), 2024
• Figure 8: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 9: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 10: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: Anti-Obesity Drugs (Prescription Drugs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: Anti-Obesity Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: Anti-Obesity Drugs (OTC Drugs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: Anti-Obesity Drugs (OTC Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: Anti-Obesity Drugs (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: Anti-Obesity Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: Global: Anti-Obesity Drugs (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: Global: Anti-Obesity Drugs (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: North America: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: North America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: United States: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 25: United States: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 26: Canada: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 27: Canada: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 28: Asia-Pacific: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 29: Asia-Pacific: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 30: China: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 31: China: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 32: Japan: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 33: Japan: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 34: India: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 35: India: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 36: South Korea: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 37: South Korea: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 38: Australia: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 39: Australia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 40: Indonesia: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 41: Indonesia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 42: Others: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 43: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 44: Europe: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 45: Europe: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 46: Germany: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 47: Germany: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 48: France: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 49: France: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 50: United Kingdom: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 51: United Kingdom: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 52: Italy: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 53: Italy: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 54: Spain: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 55: Spain: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 56: Russia: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 57: Russia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 58: Others: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 59: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 60: Latin America: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 61: Latin America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 62: Brazil: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 63: Brazil: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 64: Mexico: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 65: Mexico: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 66: Others: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 67: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 68: Middle East and Africa: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 69: Middle East and Africa: Anti-Obesity Drugs Market: Breakup by Country (in %), 2024
• Figure 70: Middle East and Africa: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 71: Global: Anti-Obesity Drugs Industry: SWOT Analysis
• Figure 72: Global: Anti-Obesity Drugs Industry: Value Chain Analysis
• Figure 73: Global: Anti-Obesity Drugs Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Anti-Obesity Drugs Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
• Table 3: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
• Table 4: Global: Anti-Obesity Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
• Table 5: Global: Anti-Obesity Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 6: Global: Anti-Obesity Drugs Market: Competitive Structure
• Table 7: Global: Anti-Obesity Drugs Market: Key Players

The global anti-obesity drugs market size was valued at USD 2.5 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 5.9 Billion by 2033, exhibiting a CAGR of 9.89% from 2025-2033. North America currently dominates the market, holding a market share of over 36.7% in 2024. The anti-obesity drugs market share is increasing due to the rising obesity rates, health awareness, demand for weight management solutions, drug development advancements, government initiatives, R&D investments, combination therapies, and availability of prescription and over-the-counter drugs.

Anti-obesity drugs are intended to reduce or control weight and generally medically prescribed only in cases of morbid obesity. They help reduce cravings and control compulsive eating, especially for sweets and fatty, salty, and high-calorie food products. They can also provide independent health benefits, such as controlling blood pressure, harmful lipid levels, waist circumference, sugar levels and nonalcoholic fatty liver disease (NAFLD) and minimize the risk of major cardiovascular diseases (CVDs) and progression of diabetic kidney disease.

Anti-Obesity Drugs Market Trends:

Recent advances in anti-obesity drugs have enabled the potential of attaining clinically significant weight loss among individuals. This, in confluence with the widespread prevalence of obesity on account of sedentary lifestyles, represents one of the key factors creating a positive outlook for the market. In addition, obesity increases the risk of developing type 2 diabetes (T2D), cardiovascular diseases (CVD), and cancer of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney. It can also result in numerous psychological, neurological, pulmonary, gastrointestinal, renal, musculoskeletal, and endocrine diseases. Besides this, sleep deprivation, circadian desynchronization, chronic stress, and the rising use of anti-epileptic and psychotropic drugs may further induce weight gain. This, coupled with the increasing number of approvals of anti-obesity medications (AOMs) that help regulate appetite and food cravings, is fueling the growth of the market. Apart from this, weight loss aids in improving the quality of life, mobility, daily function, and psychological well-being of individuals. This, along with the increasing health consciousness, thriving pharmaceutical industry, and the rising focus on the management of diseases closely integrated with excess body weight, is anticipated to stimulate the growth of the market.

Key Market Segmentation:

Breakup by Drug Class:

• Peripherally Acting Drugs
• Centrally Acting Drugs

Breakup by Drug Type:

• Prescription Drugs
• OTC Drugs

Breakup by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.

Key Questions Answered in This Report

• 1.How big is the anti-obesity drugs market?
• 2.What is the future outlook of anti-obesity drugs market?
• 3.What are the key factors driving the anti-obesity drugs market?
• 4.Which region accounts for the largest anti-obesity drugs market share?
• 5.Which are the leading companies in the global anti-obesity drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Anti-Obesity Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 Peripherally Acting Drugs
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Centrally Acting Drugs
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

• 7.1 Prescription Drugs
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 OTC Drugs
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacy
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacy
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Pharmacy
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Boehringer Ingelheim International GmbH
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Currax Pharmaceuticals LLC
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Gelesis
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 GlaxoSmithKline plc
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Merck & Co. Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Norgine B.V.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Novo Nordisk A/S
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Pfizer Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 Rhythm Pharmaceuticals Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 SHIONOGI & Co. Ltd.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Takeda Pharmaceutical Company Limited
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Vivus LLC
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio